Gelteq Limited is a biotechnology company focused on the development and commercialization of innovative drug delivery systems and therapeutic solutions. The company specializes in utilizing advanced technologies to formulate and manufacture complex pharmaceuticals, aiming to enhance the efficacy and safety of treatments. Gelteq's research initiatives are dedicated to addressing unmet medical needs across various therapeutic areas, and the company collaborates with healthcare professionals and institutions to bring its cutting-edge products to market. Through its commitment to scientific excellence and patient-centered solutions, Gelteq strives to improve patient outcomes and transform healthcare delivery. Read More
Gainers Gelteq (NASDAQ:GELS) stock moved upwards by 20.3% to $0.84 during Wednesday's after-market session. The company's market cap stands at $5.6 million. Nyxoah (NASDAQ:NYXH) shares increased by 12.58% to
September 2, 2026 - VivoSim Labs, Inc. (NASDAQ: VIVS) is expanding the potential commercial reach of its NAMkind™ drug toxicology platform, announcing plans to develop a rat liver model that would complement its existing 3D human liver model and help pharmaceutical companies distinguish animal-specific toxicity from risks that may translate to humans.
Gainers bioAffinity Technologies (NASDAQ:BIAF) stock moved upwards by 54.3% to $10.17 during Wednesday's regular session. The company's market cap stands at $3.9 million. Gelteq (NASDAQ:GELS) shares increased
NEW YORK CITY, NY / ACCESS Newswire / March 26, 2026 / Investor Summit Group is excited to share that the presentations from Q1 Virtual Conference are now available on-demand. If you missed the live event, now's your chance to catch up at your own pace.
NEW YORK, NY / ACCESS Newswire / March 20, 2026 / The Investor Summit today announced the lineup of public companies scheduled to present at its upcoming Virtual March 25-26, 2026 event.
Kartoon Studios (NYSE: TOON) is drawing heightened investor attention as political uncertainty clouds one of the media industry’s most closely watched potential mergers. President Donald Trump has publicly opposed Netflix (NASDAQ: NFLX) ’s proposed acquisition of Warner Bros. Discovery (NASDAQ: WBD), raising the possibility that his administration could seek to delay or block the transaction. While courts could ultimately overrule such action, the near-term impact would likely be prolonged uncertainty—forcing streaming platforms and content owners to reassess their growth and acquisition strategies.
Gelteq signed a three-year agreement with Shenzhen Mana Health Management to distribute its sugar-lowering nutritional products in China, guaranteeing approximately $1.3 million in minimum revenue.
